Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours

NCT03593226 is registered in ClinicalTrials.gov with Agalimmune Ltd. as lead sponsor.

NCT NCT03593226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03593226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours
Lead sponsor
Agalimmune Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2018
Completion date
December 31, 2023
Enrollment
38 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

superficial, palpable, unresectable/metastatic solid tumour